Evidence map›Paper›PMID 38438393›Full record

ArticleScientific reports2024

Development of machine learning-based predictors for early diagnosis of hepatocellular carcinoma.

Zi-Mei Zhang, Yuting Huang, Guanghao Liu, Wenqi Yu, Qingsong Xie, Zixi Chen, Guanda Huang, Jinfen Wei, Haibo Zhang, Dong Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zi-Mei ZhangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Yuting HuangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Guanghao LiuKey Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, China.
Wenqi YuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Qingsong XieSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Zixi ChenSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Guanda HuangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Jinfen WeiSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Haibo ZhangSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
Dong ChenFangrui Institute of Innovative Drugs, South China University of Technology, Guangzhou, China.
Hongli DuSchool of Biology and Biological Engineering, South China University of Technology, Guangzhou, China. hldu@scut.edu.cn.
South China University of Technology · CNFujian Medical University · CN

Funding

Key R&D Program of Guangdong Province 2019B020226001National Key R&D Program of China 2018YFC0910201
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a formidable malignancy that significantly impacts human health, and the early diagnosis of HCC holds paramount importance. Therefore, it is imperative to develop an efficacious signature for the early diagnosis of HCC. In this study, we aimed to develop early HCC predictors (eHCC-pred) using machine learning-based methods and compare their performance with existing methods. The enhancements and advancements of eHCC-pred encompassed the following: (i) utilization of a substantial number of samples, including an increased representation of cirrhosis tissues without HCC (CwoHCC) samples for model training and augmented numbers of HCC and CwoHCC samples for model validation; (ii) incorporation of two feature selection methods, namely minimum redundancy maximum relevance and maximum relevance maximum distance, along with the inclusion of eight machine learning-based methods; (iii) improvement in the accuracy of early HCC identification, elevating it from 78.15 to 97% using identical independent datasets; and (iv) establishment of a user-friendly web server. The eHCC-pred is freely accessible at http://www.dulab.com.cn/eHCC-pred/ . Our approach, eHCC-pred, is anticipated to be robustly employed at the individual level for facilitating early HCC diagnosis in clinical practice, surpassing currently available state-of-the-art techniques.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsEarly DiagnosisHumansLiver CirrhosisMachine LearningPrednisonePrednisone

Identifiers

PMID38438393
PMCPMC10912761
OpenAlexW4392375099

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.